
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Gain Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.38) per share for the year, up from their prior estimate of ($0.49). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.35) EPS.
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05.
A number of other research firms have also recently issued reports on GANX. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. BTIG Research reissued a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a report on Monday, October 5th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.
Read Our Latest Stock Analysis on Gain Therapeutics
Gain Therapeutics Trading Up 25.5%
Shares of GANX stock opened at $1.18 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.36 and a quick ratio of 5.36. The company has a market cap of $52.55 million, a price-to-earnings ratio of -2.81 and a beta of 0.29. The stock has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $1.81. Gain Therapeutics has a 1-year low of $0.94 and a 1-year high of $4.34.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new stake in shares of Gain Therapeutics in the third quarter valued at approximately $90,000. Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the third quarter worth approximately $571,000. StoneX Group Inc. purchased a new position in Gain Therapeutics during the third quarter worth approximately $44,000. BOKF NA purchased a new position in Gain Therapeutics during the third quarter worth approximately $35,000. Finally, Squarepoint Ops LLC acquired a new position in Gain Therapeutics during the second quarter worth $277,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc. is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction. The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function.
Featured Articles
- Five stocks we like better than Gain Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
